Septic shock management
Reading File
Finding Sources
Searching PubMed
"septic shock"[MeSH Terms] AND management
Searching the Web
septic shock management guidelines 2025 SSC Surviving Sepsis Campaign
Reading File
Finding Sources
Reading Web Page
septic shock management 2026 guidelines key recommendations
Finding Sources
Reading File
I now have comprehensive, multi-source data. Let me compose the full response.
Septic Shock Management
2026 Update: The Surviving Sepsis Campaign (SSC) released updated adult guidelines in April 2026 (Crit Care Med 2026;54:725-812), adding 46 new statements covering antibiotic optimisation, blood pressure targets in older adults, fluid removal after resuscitation, and post-discharge rehabilitation.
Definition (Sepsis-3)
Septic shock = sepsis + vasopressor requirement to maintain MAP ≥65 mmHg + serum lactate >2 mmol/L despite adequate fluid resuscitation. Implies circulatory, cellular, and metabolic abnormalities with substantially higher mortality than sepsis alone.
The "1-Hour Bundle" — Immediate Actions
| Time | Action |
|---|---|
| 0–60 min | Measure lactate; obtain blood cultures (≥2 sets) before antibiotics; administer broad-spectrum antibiotics; begin 30 mL/kg IV crystalloid bolus; start vasopressors if MAP <65 mmHg despite initial fluid |
| ≤6 h | ICU admission; re-measure lactate if initial >2 mmol/L; reassess fluid responsiveness |
1. Fluid Resuscitation
- Initial bolus: 30 mL/kg balanced crystalloid (Lactated Ringer's or PlasmaLyte preferred over normal saline) within the first 3 hours
- Guide subsequent fluid with dynamic assessments (pulse pressure variation, passive leg raise response, stroke volume variation) rather than static CVP
- Albumin: consider adding when very large volumes of crystalloid are required
- Avoid hetastarch (HES) — increased risk of AKI and death
- Serial lactate measurement to guide resuscitation adequacy (target clearance ≥10% per 2 hours)
- 2026 addition: active fluid removal (conservative fluid strategy/de-resuscitation) after the acute phase to prevent fluid overload — one of the new recommendations
2. Vasopressors
| Agent | Role | Dose |
|---|---|---|
| Norepinephrine | First-line; balanced α/β agonism, increases vascular tone | Start 0.01–0.25 µg/kg/min; titrate to MAP ≥65 mmHg |
| Vasopressin | Add when NE reaches 0.25–0.5 µg/kg/min (not dose escalation); steroid-sparing effect | Fixed rate 0.03–0.04 units/min |
| Epinephrine | Third-line if NE + vasopressin insufficient; also for septic cardiomyopathy | 0.01–0.3 µg/kg/min |
| Dobutamine | Add for low cardiac output/septic cardiomyopathy despite adequate preload | 2–20 µg/kg/min |
| Dopamine | Not recommended routinely; only highly selected cases (bradycardia + low risk arrhythmia) | — |
| Terlipressin, levosimendan | Not recommended | — |
Target MAP: ≥65 mmHg (the 2026 guidelines add a conditional recommendation for 60–65 mmHg targets in older adults to reduce vasopressor exposure).
3. Antimicrobials
- Timing: broad-spectrum IV antibiotics within 1 hour of sepsis/septic shock recognition — every hour of delay worsens mortality
- Blood cultures (≥2 sets, including from each vascular access site) before antibiotics but do not delay antibiotics >45 min to obtain cultures
- Empiric coverage: guided by suspected source, local resistance patterns, and host immune status; typically covers gram-positives + gram-negatives; add antifungal only in high-risk patients (prolonged neutropenia, recent surgery, TPN-dependent)
- Procalcitonin: do not use to start antibiotics; can guide de-escalation and duration
- De-escalation: reassess daily; narrow spectrum when organism and sensitivities are known; typical duration 7–10 days; consider stopping if no infectious source identified
4. Source Control
- Identify and control the infection source promptly — imaging (CT, ultrasound) to locate abscess, infected collection, necrotic tissue, or foreign body
- Drainage, debridement, or removal of infected device performed as soon as medically feasible (generally within 6–12 hours for surgical emergencies)
- Intravascular access devices that could be the source should be removed after securing alternative access
5. Corticosteroids
- Hydrocortisone 200 mg/day (50 mg IV q6h or 200 mg continuous infusion) if shock persists despite:
- Adequate fluid resuscitation AND
- Vasopressor therapy at moderate–high doses
- Can add fludrocortisone 50 µg PO daily (Annane protocol)
- Reduces duration of vasopressor requirement; no definitive mortality benefit but used for refractory shock
- Taper once vasopressors are weaned; avoid abrupt cessation
6. Organ Support
Respiratory
- Maintain SpO₂ 90–96%
- High-flow nasal cannula (HFNC) as first step if adequate neurologic status
- Mechanical ventilation if needed: tidal volume 6 mL/kg IBW, plateau pressure ≤30 cmH₂O, apply PEEP
- Prone positioning ≥12 h/day for moderate–severe ARDS (P/F <150)
- Neuromuscular blockade to facilitate proning (intermittent bolus preferred over continuous infusion)
- VV-ECMO for refractory ARDS if experienced centre available
Renal
- Avoid nephrotoxins; maintain renal perfusion
- RRT for progressive AKI, refractory hyperkalemia, uremia, or volume overload
- Sodium bicarbonate if AKI + pH <7.2
Hematologic / Transfusion
- Transfuse RBCs for hemoglobin <7 g/dL (threshold <8 g/dL in CAD or acute hemorrhage)
- Platelets: transfuse if <10,000/µL (or <20,000 with active bleeding risk)
- FFP: only for active bleeding with coagulopathy or pre-procedure
- Cryoprecipitate: fibrinogen <150 mg/dL with bleeding
Metabolic
- Insulin for glucose ≥180 mg/dL; target 140–180 mg/dL
- Stress ulcer prophylaxis in high-risk mechanically ventilated patients
- Early enteral nutrition if shock controlled within 48 h; parenteral if goals not met by day 7
7. Monitoring & Endpoints
| Parameter | Target |
|---|---|
| MAP | ≥65 mmHg (60–65 mmHg acceptable in elderly per 2026 SSC) |
| Lactate | Clearance ≥10% per 2 h; normalize to <2 mmol/L |
| Urine output | >0.5 mL/kg/h |
| ScvO₂ | ≥70% |
| Hemoglobin | 7–9 g/dL |
| Glucose | 140–180 mg/dL |
| Capillary refill time | ≤3 s (2026 SSC added CRT as a resuscitation endpoint) |
8. Additional 2026 SSC Updates
- Capillary refill time (CRT) added as a resuscitation endpoint alongside lactate
- Antibiotic timing framework: structured decision support for antibiotic timing based on illness severity and likelihood of infection
- Post-discharge care: explicit recommendations for psychological and physical rehabilitation post-sepsis
- Blood pressure target of 60–65 mmHg conditionally recommended in selected older adults to reduce vasopressor burden
Organ Dysfunction Complication Summary
(Harrison's 22e, 2025)
| System | Frequency | Key Intervention |
|---|---|---|
| Neurologic (encephalopathy) | 54% | Limit neurotoxic agents; treat underlying cause |
| Cardiovascular (shock) | 25% | Fluids + vasopressors + hydrocortisone |
| Respiratory (ARDS) | 7% | Lung-protective ventilation; prone |
| Renal (AKI) | 67% | Avoid nephrotoxins; RRT if needed |
| Hepatic dysfunction | 50% of shock | Avoid hypotension; enteral feeding |
| DIC | 35% of shock | Cryoprecipitate, FFP, platelets |
Sources: Barash's Clinical Anesthesia 9e; Harrison's Principles 22e (2025); Goldman-Cecil Medicine; Rosen's Emergency Medicine; 2026 Surviving Sepsis Campaign Guidelines (Crit Care Med 2026;54:725-812, PMID 41869847).
iPD cardex for septic shock
Asking for Preferences
Reading File
Running Command
Running Command
Writing File
Running Command
Running Command
Running Command
File is valid (20.4 KB, clean XML). Here's your download:
Septic Shock iPD Cardex
Word Document · DOCX
What's inside the cardex (12 colour-coded sections):
| # | Section | Contents |
|---|---|---|
| 1 | Patient Header | Name, MRN, age/sex/weight, allergies, source, consultant |
| 2 | Monitoring & Targets | 14 parameters with numeric targets and frequency |
| 3 | Investigations | 17 tests — timing, purpose, result column |
| 4 | Fluid Resuscitation | Initial bolus → dynamic challenges → de-resuscitation (2026 SSC) |
| 5 | Vasopressors & Inotropes | NE → vasopressin → epi → dobutamine with doses and lines |
| 6 | Antimicrobials | 1-hour rule, cultures, empiric regimens (community vs. HAP), de-escalation |
| 7 | Source Control | Timing, drainage, debridement, device removal by source type |
| 8 | Corticosteroids | Hydrocortisone 200 mg/day + fludrocortisone, taper protocol |
| 9 | Respiratory Support | SpO₂ targets, HFNC, lung-protective MV settings, proning, ECMO |
| 10 | Organ Support | Renal, transfusion thresholds, glucose, nutrition, SUP, DVT, sedation |
| 11 | Medication Chart | 10 common drugs with dose/route/frequency/indication + signature box |
| 12 | Nursing Care Plan | 7 care problems with interventions |
| 13 | Escalation / Red Flags | 10 thresholds with immediate actions |
Based on SSC 2026 Guidelines (Crit Care Med 2026;54:725-812) + Harrison's 22e + Rosen's EM.
This is a shared conversation. Sign in to Orris to start your own chat.